相关实验视频
Updated: Jun 21, 2025

07:27
Olfactory Assays for Mouse Models of Neurodegenerative Disease
Published on: August 25, 2014
22.0K
嗅觉丧失与肌缩侧面硬化症患者的认知障碍有关
Xin Huang1, Jieying Wu1, Nan Zhang1
1Department of Neurology, Peking University Third Hospital, Beijing, China.
CNS neuroscience & therapeutics
|July 9, 2024
概括
嗅觉丧失与肌缩性侧面硬化症 (ALS) 患者的认知障碍有关. 这表明前功能障碍可能会影响ALS患者的嗅觉性能.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 嗅觉研究 嗅觉研究
背景情况:
- 嗅觉丧失显著影响生活质量.
- 有限的研究存在于氨基转移性侧面硬化症 (ALS) 中的嗅觉丧失.
- 在ALS中嗅觉丧失和认知障碍之间的相关性尚不清楚.
研究的目的:
- 研究ALS患者的嗅觉丧失和认知障碍之间的相关性.
- 探索嗅觉功能和ALS的认知状态之间的关系.
主要方法:
- 这项研究包括216名ALS患者.
- 用爱丁堡认知和行为ALS屏幕 (ECAS) 评估认知功能.
- 用中国气味识别测试 (CSIT) 评估了嗅觉功能.
主要成果:
- 在对共变量进行调整后,CSIT分数与ECAS分数 (r=0.162,p=0.028) 显著相关,特别是ALS特定分数 (r=0.158,p=0.031).
- 除了患有尿路感染或鼻炎的患者,结果相似,CSIT分数与ECAS分数 (r=0.224,p=0.011) 和ALS特异性分数 (r=0.205,p=0.019) 相对应.
结论:
- 嗅觉丧失与ALS患者的认知障碍有显著的相关性.
- 前功能障碍特别与ALS的嗅觉丧失有关.
- 认知功能障碍可能导致ALS患者的嗅觉表现较差.
相关概念视频
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177

